NCT07307690Not yet recruiting
8 Weeks vs 12 Weeks Physical Exercise Programmes in Colorectal Cancer Patients
Comparison of the Effectiveness of 8-week vs 12-week Physical Exercise Programmes in Patients With Colorectal Cancer
Source: ClinicalTrials.gov · Last updated 6 Jan 2026
Brief summary (registry, in English)
Chemotherapy is a cornerstone in the treatment of colon cancer; however, its effects extend beyond malignant cells. Because chemotherapeutic agents target rapidly dividing cells, they can also damage healthy tissues, resulting in a range of adverse effects. Among the most prevalent is peripheral neuropathy, a disorder of the peripheral nervous system characterized by symptoms such as tingling, numbness, pain, and weakness in the extremities. Chemotherapy-induced peripheral neuropathy poses a significant challenge for patients with colon cancer, as it further compromises quality of life during an already demanding phase of treatment. Damage to sensory and motor nerves interferes with the ability to perform daily activities and diminishes physical capacity, thereby intensifying both the physical and psychological burden associated with the disease. Nevertheless, certain interventions may help mitigate these negative effects, with physical exercise emerging as a particularly promising strategy. Although it may appear counterintuitive, regular physical activity has been shown to exert beneficial effects on peripheral neuropathy. Exercise enhances blood circulation, supports the regeneration of damaged peripheral nerves, and helps reduce neuropathic pain and discomfort, ultimately improving functional performance. It is important to emphasize that exercise interventions should be individually tailored and conducted under appropriate medical supervision. Consequently, the integration of chemotherapy with a carefully designed exercise program represents a comprehensive approach to managing both the disease and its treatment-related side effects, contributing to an improved quality of life for patients with colon cancer throughout their recovery process.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 13 Dec 2025
- Start date
- 1 Jan 2026
- Primary completion date
- 1 May 2026
- Lead sponsor
- University of Salamanca
- Diseases
- Colorectal cancer
- NCT number
- NCT07307690
What you commit to
- Study type: Interventional
- Planned participants: 50
- From 1 Jan 2026 to the primary completion date, 1 May 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- \- Present contraindication/s for physical exercise (musculoskeletal diseases, severe cardiovascular disease, bone metastases,...).
Who the study is looking for
- People diagnosed with colorectal cancer and who are receiving chemotherapy treatment.
- Sedentary people who have not performed physical activity in the last 8 weeks.
- Ability to understand the evaluation tests and the performance of the exercises.
- Presence of XXX symptoms (If we focus on neuropathy, it should be inclusion criteria).
- Voluntary participation in the study.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.